Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution

Yu Zhang 1,2, Li-Min Chen 1,2,3 and Miao He 1,2*

Abstract
Due to the low fidelity of the RNA-dependent RNA polymerase, Hepatitis C virus (HCV) mutates quite frequently. There are seven genetically divergent genotypes (GTs) distributed in the world, each of which contains several closely related subtypes. The peer-reviewed literatures reporting the prevalence rate of HCV GTs in Chinese hospitalized patients were identified by systematic searching of three electronic databases, and the prevalence rates were pooled through 137 qualified studies. The significant difference between HCV GT and HCV viral load and severity of hepatitis were analyzed under Chi-squared or Fisher's exact test. Data from epidemiological studies on hospitalized patients demonstrated that HCV GTs 1–6 have been found in China, of which 1b (62.78% (95% CI: 59.54–66.02%)) and 2a (17.39% (95% CI: 15.67–19.11%)) are the two predominant subtypes. HCV GTs and subtypes exhibits significant regional divergence. In North, Northwest, Northeast, East (except Jiangxi province) and Central China (except Hunan province), HCV-1b, 2a remain the two predominant subtypes; South China shows the most abundant genetic diversity that 14 subtypes were found, and HCV-3 in the Southwest China remains higher prevalent subtype than the other regions. In addition, co-infection in Liaoning province of Northeast China is the most diverse with 10 co-infection types, and Tibet has the highest rate of co-infection. The associations between HCV GTs and patients group, severity of illness and antiviral treatment efficacy were also discussed in this review.

Keywords: HCV genotype, Subtypes, Distribution, Co-infection, Population demographics, Antiviral treatment efficacy

Background
Hepatitis C virus (HCV) is a globally distributed hepatic virus with an estimated 130 to 150 million people (2 to 3% of the world’s population) chronically infected world widely [1, 2]. It has been reported that by 2025, HCV-related mortality will be tripled [3]. HCV infection constitutes over 70% of post-transfusion hepatitis (PTHC), and is one of the leading causes of chronic liver disease, which usually results in liver cirrhosis (LC), liver failure and hepatocellular carcinoma (HCC) within 20 to 30 years following infection [4–6]. HCV incidence in China was 0.06‰, however, in some area such as in Fujian, reached as high as 6.01% in 2010 [7]. HCV infection has become the second major type of viral liver disease only next to Hepatitis B virus (HBV) infection in China [8], and exhibits great threat to public health.

Hepatitis C virus (HCV) was classified into genus Hepacivirus of family Flaviviridae [6]. Like other positive-stranded RNA viruses, the HCV genome encodes a single polyprotein with approximately 3000-amino-acids in length with the following order: 5'-C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-3' [9], and flanks with 5' and 3' untranslated regions, which consists of 341 and 27 bases, respectively [10]. HCV genome has high genetic heterogeneity with as much as 30% of sequence divergence [11]. Based on the sequence divergence, HCV was classified into seven different genotypes (GTs) and more than 90 subtypes [6, 12]. The greatest genetic diversity was observed within HCV-6, with 24 subtypes (6a-6xa) being classified [13, 14].

In China, HCV GT distribution has been associated with various geographical and demographic characteristics. Due to the increasing mobility of the population

* Correspondence: mesa1022@126.com
1Institute of Blood Transfusion, Peking Union Medical College, Chinese Academy of Medical Sciences, Chengdu 610052, China
2Sichuan Blood Safety and Blood Substitute, International Science and Technology Cooperation Base, Chengdu 610052, China
Full list of author information is available at the end of the article

© The Author(s), 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
and different transmission routes, HCV GTs distribution changed gradually and co-infection with multiple subtypes as well as genetic recombinant appeared frequently in some regions. Most recently, three new subtypes have been characterized in China: HCV-1b-2a, 1b-2k and 6d-6k [15]. Since there is a paucity of data from large-sample study of HCV GT distribution in China, this review aims to describe the most comprehensive distribution of HCV GTs in mainland China in order to facilitate personalized treatment and to further understand the virology of HCV for vaccine and antiviral drug development in China.

**Methods**

**Literature search**
The literature search on HCV GT detection among clinical cases in mainland China was conducted using China National Knowledge Infrastructure (CNKI), PubMed and Wanfang Data (a Chinese professional academic database developed by Wanfang data limited-liability Company) with the key words “HCV” or “Hepatitis C virus”; “genotype” or “subtype”, “sequencing” or sequence analysis”; “transfusion transmitted disease” and “China” or “Mainland China”. No language restrictions were applied.

**Literature selection and data extraction**
The inclusion criteria included: 1) The study was conducted only in mainland China (Hong Kong, Taiwan and Macao were excluded); 2) Studies involving the HCV genotype and (or) subtype distribution; 3) The study object were hospitalized patients; 4) Studies with clear sample size.

The exclusion criteria were as follows: 1) studies without exact sample size, publication year and methods; 2) Overlapping or paradoxical studies: data from literature were repeat or inconsistent between the context; 3) The study objects were blood donors or intravenous drug user; 4) HCV GTs prevalence rate in patients with HIV/HCV co-infection; 5) Comments, reviews or conference abstracts. When investigating the trends of HCV GT spatio-temporal distributions, literatures without exact study year were not included.

**Statistical analysis**
Pooled results for the prevalence rate of HCV GTs and corresponding 95% CIs by meta-analysis based on Chi-squared or Fisher’s exact test of crosstabs, and $P$ value <0.05 represents statistical significance.

**Results**

**HCV GT distribution**

**A profile of HCV GT data**

Related data were collected: 193 studies [6–8, 12, 13, 16–203] considering methods used for HCV genotyping (Table 1); 137 clinical studies [7, 8, 12, 13, 16–146, 202, 203] with a total of 19712 HCV hospitalized cases considering prevalence rate of HCV subtypes [Fig. 1].

Commonly used molecular biology methods for HCV genotyping include DNA sequence assay (a gold standard), type specific primers amplification method, restriction fragment length polymorphism (RFLP), gene chip assay, and probe hybridization. Multiple methods targeting different regions of the HCV genome have been used for classifying GTs. The most accurate method is to sequence an appropriate coding region that varies enough for phylogenetic analysis to distinguish genotypes and subtypes [204, 205]. Although the 5’ untranslated region (5’UTR) has most often been used by clinical laboratories for routine genotyping considering its high level of conservation, the 5’UTR is limited in its ability to discriminate GT 6 from GT 1 and subtypes within GTs 1, 2, 3, 4, and 6 [14, 206]. Nowadays, the three most commonly used regions for determining the HCV GT and subtypes are Core, E1, and NS5B [14, 207] with high accuracy and sensitivity.

**HCV GT distribution among clinical cases in mainland China**
The dominant HCV GTs in most Asian countries are HCV-1, 3 [208]. Although six GTs (GTs 1 to 6), 24 subtypes (subtypes 1a, 1b, 1c, 2a, 2b, 2i, 2f, 2k, 3a, 3b, 3k, 4, 5a, 6a, 6b, 6d, 6e, 6g, 6h, 6k, 6n, 6u, 6v, and 6w), and a number of unassigned HCV variants have been detected in China, over 95% of these isolates belong to five major subtypes: 1b, 2a, 3a, 3b, and 6a [12, 177, 209–214].

The prevalence rate of HCV GTs in various regions of mainland China was pooled, and corresponding 95% CIs was also further tabulated (Table 2). Although HCV GTs 1–6 have been found in China, GTs 1b and 2a were the two major HCV subtypes, accounting for 62.78% (95% CI: 59.54–66.02%) and 17.39% (95% CI: 15.67–19.11%), respectively. In 70% (22/30) of provinces, HCV-1b, 2a are still the most prevalent. The major GTs in Jiangxi, Guangdong, Hunan and Guangxi were 1b, 6a, while in Yunnan, Sichuan, Guizhou and Chongqing were 1b, 3b. In Yunnan Province, 3b and 1b was the predominant HCV subtypes. HCV GT distribution also exhibits significant region divergence (Fig. 2). The major subtypes in North China, Northwest and Northeast were 1b and 2a, although 1a, 1c, 2b, 2c, 2i, 2k, 3a, 3b, 3k, 4, 6a were also identified. In East and Central China, HCV-1b, 2a...
remain the two predominant subtypes except Jiangxi and Hunan province with the popular subtypes 1b and 6a. In Southwest and South China, HCV-1b, 3b/6a was the predominant subtype. South China region showed the most abundant genetic diversity with 14 subtypes (1a, 1b, 1c, 2a, 2b, 2f, 3a, 3b, 4, 5a, 6a, 6d, 6e, 6n) being found, and HCV-3 in the Southwest remains higher prevalent subtype than other regions, which was consistent with previously published studies [212, 215].

HCV GT distribution reported by various Chinese regions is experiencing a remarkable change over time. An annual decrease of 1b, 2a, and an increase of GT 3a, 3b, 6n and 6a were reported in Henan, Jiangsu, Zhejiang, Chongqing, Tianjin and Yunnan [13, 16, 25, 90, 136, 152, 191, 216, 217]. We also screened qualified literatures from the hospitalized cases, and three periods (before 2005; 2005–2010; after 2010) were divided to summary respective prevalence rate of HCV GT. Comparison of prevalence rate over time was then performed to get the changing trend of HCV GT distribution. Our results showed that in Southwest and South China, HCV GT distribution experienced a significant change (P < 0.05) (Table 3) that the proportion of subtypes 1b, 2a were decreasing and yet GT 3 were increasing over time. In addition, HCV subtype 4, 5, 6v, 6d, 6u have also been found in some areas of China in recent years [191, 210, 211, 213, 218]. This changing trend may result from the increasing population mobility, various transmission routes, and the improved sensitivity and specificity of testing methods.

**HCV GT characteristics of co-infection in China**

Presence of multiple HCV subtypes, increasing of population mobility and drug abusers, more convenient use of hemodialysis and improved detection methods increase the incidence of reported co-infection with multiple subtypes and genomic recombination. Till now, at least 5 subtypes of co-infection have been reported in China [170, 219].

In recent years, HCV GTs exhibit an increased percentage of co-infection, of which the most common in China was 1b/2a co-infection, and GTs 2a/2b and 1b/2b co-infection were occasionally reported, which may affect the host immune responses and treatment outcomes [220–222]. It was reported that among 1450 HCV RNA positive plasma (serum) samples collected

---

**Table 1 Methods used for HCV genotyping in mainland China**

| Region          | Province          | Genotyping method                                                                 | Amplified fragment                                                                 |
|-----------------|-------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Central China²*| Hunan, Hubei, Henan| Nested-PCR and sequence analysis, PCR-RDB, GT-specific primers PCR method, gene chip assay | Core and E1, NS5B and/or Core-E1, NS5B, 5′UTR, core |
| East China²*    | Shandong, Jiangsu, Anhui, Jiangxi, Fujian, Shanghai, Zhejiang| Nested-PCR and sequence analysis, RFLP, GT-specific primers PCR method, gene chip assay | 5′-UTR, core, NS5B and/or core-E1, 5′-UTR and/or NS5B, NS5B and C/2E, core and NS5B and 5′-UTR, E2, NS5B and E2 |
| South China³*   | Guangdong, Guangxi, Hainan | Nested-PCR and sequence analysis, GT-specific primers PCR method, gene chip assay, PCR – RDB, LIPA | NS5B and E1, core and NS5B, E1, NS5B, 5′-UTR and NS5B |
| North China⁴*   | Beijing, Shanxi, Tianjin, Hebei, IM | RFLP, Nested-PCR and sequence analysis, GT-specific primers PCR method, gene chip assay, PCR fluorescent probe method | Core, C/E1, 5′-UTR |
| Southwest⁵*     | Sichuan, Yunnan, Chongqing, Guizhou | gene chip assay, RFLP, Nested-PCR and sequence analysis, PCR-RDB, Type specific probe hybridization method | 5′-UTR, 5′UTR-core and E1-E2 and NS5B, 5′NCR-C and NS5B, core/E1 and NS5B, E1/E2 and NS5B, 5′-UTR Core, core and E1, core, C/E1, NS5B |
| Northwest⁶*     | Gansu, Sha anxi, Xinjiang | Nested-PCR and sequence analysis, RFLP, PCR-RDB,GT-specific primers PCR method,LIPA, restriction endonuclease cleaving method | E1 and NS5B, 5′NCR, NS5B |
| Northeast⁷*     | Liaoning, Heilongjiang, Jilin | RFLP, Nested-PCR and sequence analysis, PCR – RDB, type-specific primers PCR method, gene chip assay | NS5, Core, 5′UTR, C and E1 and NS5 |

**PCR-RDB:** Polymerase chain reaction-reverse dot blot; **RFLP:** Restriction fragment length polymorphism

**LIPA:** Line probe hybridization method

1*: See reference [7, 16–30, 131, 155, 193]

2*: See reference [6, 8, 31–67, 132–139, 147–150, 156–166, 199, 201]

3*: See reference [12, 13, 67–82, 167–178, 202]

4*: See reference [83–89, 145, 151, 152, 179–182, 203]

5*: See reference [82, 90–102, 153, 179, 188–192, 194–198]

6*: See reference [103–120, 141–144, 146, 184–187]

7*: See reference [121–130, 140, 154, 183]
randomly from general and infectious disease-specialized hospitals of the capital city from all provinces (except Taiwan), municipalities (except Chongqing), and autonomous regions (except Xinjiang), 11 was reported as HCV co-infection. These co-infection with multiple subtypes involved 1b, 2a and 6a, of which 1b/2a was the most common, accounting for 81.8% (9/11) and followed by 6a/2a and 6a/1a, which is also the first time for HCV co-infection in China that the GT 6a was found [223]. Patients who repeatedly received blood, used to share needles as intravenous drug users (IDUs) and routinely performed dialysis contributed significantly to multiple HCV genotypes/subtype co-infection in China [222, 224]. According to our statistical analysis, co-infection in Liaoning province of Northeast China is the most diverse with 10 co-infection types, and Tibet has the highest rate of co-infection, which might suggest that there had a relatively high proportion of patients who would be a repeated recipient, an IDU, or a dialysis patient. In addition, it was reported that HCV triple infections kept a relatively high percentage in Gansu, of which GTs 1a/1b/2a or 1a/1b/2c were more popular, accounting for 20.6% (14/68) infections [186].

In addition, HCV subtype 6a was most common in patients with HIV/HCV co-infection, and was mainly spread through intravenous drug use [225, 226].

HCV GTs and different population demographics

HCV GT distribution usually varied in different populations such as in blood donors, IDUs, hemodialysis patients (HDs) and hepatitis patients. The distribution pattern changes with the change of transmission modes [227]. Generally, transfusion transmitted HCV were strongly associated with subtypes 1b and 2a [89, 180, 181]. Encouragingly, the paid blood donation is not common in China with the implementation of the Blood Donation Law in 1998. In voluntary blood donors, GTs 1b and 2a account for the highest proportion [228], and HCV GT distribution exhibits significant geographical difference: The most common GTs in Shanxi, Henan, Jiangsu, Anhui, Shanghai, Shaanxi, Hebei and Xinjiang are 1b and 2a; the prevalent GTs in Guangdong and Fujian Province are 1b and 6a; the dominant GTs in Chongqing and Yunnan are 3a and 2a/3b; GTs 1b, 1a and 1b, 3b are most common in Guangxi and Qinghai, respectively. In addition, the proportion of subtypes 1b and 2a in volunteers decreased in recent years, and yet subtypes 3 and 6 increased [179, 229]. Some reasons may explain this GT shift: 1) Increasing of drug abuser and commercial sex activity resulted in transmission from high risk population to general population; 2) Upgrade of genotyping methods accompanied by new HCV GTs and subtypes. Among IDUs, HCV-1a, 1b, 2a, 3a, 3b, 6a, 6n and 6u have been found, of which HCV-6a and 3b/3a/1b were the most popular GTs. In HD patients, the prevalence of genotype 1 is the highest, and HCV GTs among HDs are very complex with the co-infection accounting for a big proportion [224, 230, 231], which may be ascribed to long-term dialysis, repeatedly blood transfusion and iatrogenic factors. In addition, some cases of subtype 2a are found in individuals with high risk sexual behaviors, while 1b was more popular in clinical cases [194, 232, 233].

According to statistic results, discrepancy results displayed the association between HCV GTs and gender, age in infected patients. Most studies showed no statistical difference between HCV GT and gender [7, 20, 31, 136, 137, 234], while the rest displayed significant difference, of which the proportion of subtype 1b was higher in male than in female. And on the contrary, subtype 2a showed the opposite distribution [13, 32, 40, 83, 156]. The reasonable explanation for this significant difference may be that different genders exhibit different immune response against HCV infections with different GTs. For the relationship between HCV GT and age, most studies reported no statistical difference. However, there were a few studies showed that GT 1 and 2 were more common in the older group while GT 3 and 6 in the younger group [78, 137, 235]. The reason may be ascribed to be that the transmission routes are more inclined to blood transfusion in the elder group and the main GTs were HCV-1 and 2. While in the younger
## Table 2  HCV GT/subtypes distribution in mainland China

| Study location | Province | The dominated two GTs in each province | The other distributed GTs |
|----------------|----------|----------------------------------------|--------------------------|
| East China     | Shandong | 1b 67.74% (95% CI: 60.94–74.53%)       | 6a, 1a, 3a, 3b           |
|                |          | 2a 27.57% (95% CI: 22.76–32.38%)      |                          |
|                | Jiangsu  | 1b 75.77% (95% CI: 72.47–79.07%)      | 2i, 3b, 3a, 1a, 6a, 2b, 6 h, 1c, 6b |
|                |          | 2a 11.01% (95% CI: 8.77–13.25%)       |                          |
|                | Anhui    | 1b 66.45% (95% CI: 47.57–85.32%)      | 3b, 3a, 6 k, 1a, 2b     |
|                |          | 2a 16.52% (95% CI: 8.77–24.28%)       |                          |
|                | Zhejiang | 1b 67.95% (95% CI: 56.70–79.20%)      | 3b, 3a, 6a, 1a          |
|                |          | 2a 21.82% (95% CI: 10.90–32.73%)      |                          |
|                | Jiangxi  | 1b 70.28% (95% CI: 52.38–88.19%)      | 2a, 2b, 3a, 3b          |
|                |          | 2a 11.01% (95% CI: 8.77–13.25%)       |                          |
|                | Fujian   | 1b 66.17% (95% CI: 33.93–98.4%)       | 3b, 6a, 3a, 2b, 6b      |
|                |          | 2a 17.42% (95% CI: 11.45–23.39%)      |                          |
|                | Shanghai | 1b 80.14% (95% CI: 69.64–90.63%)      | 3a, 3b, 1a, 6n, 6a      |
|                |          | 2a 13.28% (95% CI: 8.22–18.35%)       |                          |
| South China    | Guangdong| 1b 63.91% (95% CI: 58.48–69.34%)      | 2a, 3b, 3a, 1a, 6e, 6n, 4, 2b, 5a, 6a |
|                |          | 6a 17.32% (95% CI: 14.44–20.21%)      | 1c, 2f                  |
|                | Guangxi  | 1b 56.46% (95% CI: 50.73–62.20%)      | 3b, 1a, 2a, 3a, 6d      |
|                |          | 6a 12.88% (95% CI: 9.00–16.75%)       |                          |
|                | Hainan   | 1b 62.50% (95% CI: 51.32–73.68%)      | 3a                      |
|                |          | 2a 29.17% (95% CI: 18.67–39.67%)      |                          |
| North China    | Beijing  | 1b 70.41% (95% CI: 65.95–74.87%)      | 1a, 2b, 3a              |
|                |          | 2a 22.15% (95% CI: 17.22–27.08%)      |                          |
|                | Hebei    | 1b 46.56% (95% CI: 40.69–52.44%)      | 1a, 2b, 3a              |
|                |          | 2a 36.69% (95% CI: 30.05–43.34%)      |                          |
|                | Shanxi   | 1b 67.22% (95% CI: 57.44–77.00%)      | 1a, 3a                  |
|                |          | 2a 13.51% (95% CI: 6.37–20.65%)       |                          |
|                | Tianjin  | 1b 84.21% (95% CI: 72.62%–95.8%)      | 1a, 3a, 6a              |
|                |          | 2a 13.16% (95% CI: 2.41–23.91%)       |                          |
|                | Inner Mongolia | 1b 63.27% (95% CI: 38.34–88.20%)   | 3a, 1a                  |
|                |          | 2a 33.33% (95% CI: 11.97–54.70%)      |                          |
| Central China  | Hunan    | 1b 41.04% (95% CI: 33.71–48.37%)      | 3b, 2a, 3a, 5a          |
|                |          | 6a 18.50% (95% CI: 12.71–24.28%)      |                          |
|                | Hubei    | 1b 74.08% (95% CI: 66.69–81.47%)      | 3b, 6a, 3a, 1a, 2b, 6b |
|                |          | 2a 12.68% (95% CI: 8.91–16.46%)       |                          |
|                | Henan    | 1b 78.57% (95% CI: 62.47–94.66%)      | 6a, 3a, 3b, 1a          |
|                |          | 2a 14.26% (95% CI: 5.71–22.8%)        |                          |
| Southwest      | Sichuan  | 1b 78.84% (95% CI: 73.01–84.66%)      | 2a                      |
|                |          | 3b 8.47% (95% CI: 4.50–12.43%)        |                          |
|                | Yunnan   | 3b 49.50% (95% CI: 38.01–60.98%)      | 3a, 2a, 6n, 6a          |
|                |          | 1b 20.52% (95% CI: 16.31–24.73%)      |                          |
|                | Tibet    | 1b 49.63% (95% CI: 41.27–58.0%)       | 1a                      |
|                |          | 2a 16.38% (95% CI: 5.30–38.06%)       |                          |
|                | Guizhou  | 1b 35.22% (95% CI: 30.92–39.52%)      | 6a, 3a, 2a, 1a, 2b, 6d  |
group, the patients were mainly infected by HCV-3 and 6 via intravenous drug abuse and high risk sexual behaviors. However, one study in 2012 showed that subtype 1 was found more often in younger patients (<40) [125], and another report showed no statistical difference between HCV-2a and age [78]. In view of the above discrepancy results, a large-scale multiple-center study involved a wider area is needed to clarify the association between HCV GT and age or gender in China.

HCV GTs and viral loads

Many present studies were designed to determine the association between HCV GTs and viral loads in chronic hepatitis patients. It has been well known that HCV genotype/subtype together with viral load variations during treatment are very important to guide the therapeutic strategies and relapse rates [236]. However, many discrepant results were reported. Generally speaking, the higher HCV RNA loads would cause more severe liver damage with more obvious clinical manifestations [78]. The viral load in patients chronically infected with HCV is associated with GTs that the level of HCV RNA in HCV-1 patients is higher than that in GT non-1, and HCV-1 and 6 is higher than HCV-2 and 3 [52, 77, 78, 96, 152, 237], which might be due to more efficient viral replication of GTs 1 and 6 [238–240]. Some foreign studies also reported the similar results [241]. However, another study reported that among patients with high viral load in China, HCV 2a was more common than other GTs [113], while some foreign studies reported that genotype 3 or 4 were found to be significantly higher viral load as compared to other genotypes [242, 243]. In addition, higher levels of viral load were also seen in HCV co-infection [156]. Interestingly, some other studies found no significant correlation between HCV GTs and viral loads [31, 52, 78, 92, 101, 135, 153].

Considering these conflicting and complex results above, we extracted the qualified literature [17, 18, 32, 33, 44, 83, 133, 135, 152, 202, 234, 244] from the screened hospitalized patients to summary the related cases in mainland China among different GTs based on HCV RNA quantitative level (<10^6 copies/ml indicates low viral load; ≥10^6 copies/ml indicates high viral load), and performed the statistical analysis of between them. The overall result showed significant statistical difference (P < 0.05), which indicate HCV GT is associated with HCV viral load. No significant difference between subtypes 2a and 3a was found, and the significant difference was found in the other subtypes (Table 4) that HCV RNA level with subtypes 1b and 6a was higher than 2a, 3a and 3b. Various factors may be taken into account: 1) Different viral replication ability among various subtypes; 2) Regional GT distribution difference; 2) HCV infection time was not restricted exactly and identified in the same or similar stage. Since high viral load is difficult to treat than low viral load, we suggest precise mechanism study should be performed to ascertain the correlation between HCV genotypes and viral load and to further design the therapeutic strategies.

HCV GTs and severity of hepatitis

The varied HCV GTs, subtypes and strains showed different degree of liver damage [83, 245, 246]. Subtype 1b, which has more efficient viral replication ability and

### Table 2 HCV GT/subtypes distribution in mainland China (Continued)

| Location   | GT Subtypes Distribution | 1b (%) CI | 2a (%) CI | Other GTs |
|------------|--------------------------|----------|----------|-----------|
| Chongqing  | 1b 32.21% (95% CI: 25.04–39.38%) | 3b 21.86% (95% CI: 7.99–35.73%) | 2a, 6a, 3a, 1a, 6b, 2b, 3 k |
| Northwest  | 1b 50.74% (95% CI: 42.35–59.14%) | 2a 40.39% (95% CI: 32.15–48.62%) | 6a, 3a, 3b |
| Shaanxi    | 1b 56.07% (95% CI: 49.91–62.23%) | 2a 26.74% (95% CI: 16.44–37.03%) | 1c, 1a, 2c, 3a, 2b, 3b |
| Gansu      | 1b 62.71% (95% CI: 60.10–65.33%) | 2a 18.10% (95% CI: 11.99–24.2%) | 1a, 3a, 2b, 3b, 4, 6a |
| Xinjiang   | 1b 49.08% (95% CI: 30.01–68.16%) | 2a 33.8% (95% CI: 26.84–40.76%) | 3b, 3a |
| Qinghai    | 1b 48.46% (95% CI: 41.29–55.62%) | 2a 37.73% (95% CI: 28.82–46.65%) | 2c, 2b, 1a, 3a |
| Northeast  | 1b 44.87% (95% CI: 24.30–65.44%) | 2a 34.37% (95% CI: 11.24–57.50%) | 1a, 2i, 3a, 1c, 2b, 3b, 3 k, 2 k |
| Heilongjiang| 1b 56.44% (95% CI: 50.51–62.38%) | 2a 31.96% (95% CI: 19.42–44.50%) | 2b, 1a, 3a |
poor prognosis and possesses major proportion of severe liver disease (LD), is associated with HCV-related LC and HCC [83, 88, 117, 158, 247] than non-1b subtypes. The viral genome rapid replication is higher in patients with GT 1 than that in other GTs. As a result, the consequent liver histological grading and hepatitis progress speed are considerably higher than those of GT 2 infected patients, which would lead GT 1 more incline to progress into HCC consistently with previous report [87]. A study found that 5 patients with LC among 94 cases were all GT 1b [50], while 1a, 2a, 2b, 3a were more common in chronic hepatitis patients without LC and liver cancer [117, 248]. Patients infected with subtype 4 were also reported to be associated with the decompensated liver complications [249], and this strong cytotoxic effect may be associated with specific proteins encoded by subtype-specific mutant genes [250, 251]. However, other research showed that no significant differences were found between HCV GTs and outcome of HCV infections [31, 96, 128, 252]. Even so, consistent results reported presently in and out of the county were found that 1b account for a larger proportion in moderate and severe chronic hepatitis and LC than in acute, mild chronic hepatitis [253, 254], which may give us some suggestion that a proactive clinical management should be important for patients infected by HCV 1b. In addition, researches launched outside China also showed that HCV-GT 3 was associated with severe LD [255, 256].

Considering these conflicting and complex results above, we extracted the qualified literature [8, 41, 59, 65, 83, 85, 87, 96, 97, 126, 128, 140] from the screened hospitalized patients to summary the related cases in

---

Figure 2: Map of HCV GT/subtypes distribution in various regions of mainland China. The seven colors in the map represent Chinese seven divisional regions; the vertical bars indicate the top five subtypes in the different region of mainland China; the horizontal bars in the lower left corner indicate the HCV genotypes and subtypes found in mainland China. The colored arrows marked in the below of genotype distribution in South and Southwest China indicates the proportion trend change of HCV genotypes with time: subtypes 1b and 2a decreased with red arrow, and genotype 3 increased with green arrow.
mainland China among different GTs based on severity of hepatitis (chronic hepatitis; cirrhosis; hepatocellular carcinoma), and performed the statistical analysis. The overall result showed significant difference ($P < 0.05$), which may indicate HCV GT is associated with severity of hepatitis. Significant difference was found between subtypes 1b and 2a, 3b, and the significant difference was not found in the other subtypes (Table 5). The possible reason for subtype 1b being more inclined to cause severe LD than subtypes 2a and 3b may be that subtype 1b has stronger pathogenicity and replication ability. In addition, the host factor should also be considered. Based on the above results, this may provide useful and instructive information for clinical treatment, and further mechanism study may be badly needed to clarify the association between HCV GTs and severity of hepatitis.

**HCV GTs and antiviral treatment efficacy**

In China, the current standard-of-care (SOC) for the treatment of patients chronically infected with HCV is the combination therapy of PEGylated interferon alpha and ribavirin (PEG-IFN and RBV, PR); however, HCV GT is an important viral factor to predict therapeutic response and duration of treatment [257, 258]. Various genotypes of HCV have showed different treatment effects. Patients with GT 2 and 3 can achieve relative high SVR of 70–80%, yet patients with GT 1 and 4 showed bad effect with the low SVR of 40–50% [259–262]. This may be ascribed to the different pathogenicity and replication ability of HCV with different GTs and the host cell factor [263, 264]. However, the mechanism still need to be clarified in the future, and some previous studies have reported that this may be associated with increased amount or mutation of E2 protein and the binding of NS5A protein to the protein kinase (PKR) [265, 266], a kind of antiviral protein normally induced by IFN during treatment.

With the development of new potent DAA and its combinations, the cure rate of HCV infection reaches >90% in almost all HCV GTs and stages of LD [267, 268]. Especially, Epclusa, the first oral fixed-dose combination, shows high SVR for all six major HCV genotypes, and even in patients with decompensated cirrhosis, the SVR12 can achieve 94% [269]. Actually, China has completed the clinical trials of some DAA drugs that sofosbuvir - daclatasvir or Harvoni, daclatasvir + asunaprevir, Ledipasvir/sofosbuvir and sofosbuvir + PEG/RBV are all safe and effective in Chinese patients with chronic hepatitis C [270]. Unfortunately, this DAA combination therapy is not cost-effective and for the moment, PR remains a good alternative to treat Chinese patients chronically infected with HCV with above 80% SVR which is higher than that in Europe and America [271].

### Table 3 Proportion change significance of HCV GT distribution with time in South and Southwest China

| Region     | Subtype | Year       | Proportion       | $P$  |
|------------|---------|------------|------------------|------|
| South China| 1b      | Before 2005| 63.35% (159/251) | <0.05|
|            |         | 2005–2010  | 63.09% (400/634) |      |
|            |         | After 2010 | 55.00% (363/660) |      |
|            | 2a      | Before 2005| 14.34% (36/251)  | <0.05|
|            |         | 2005–2010  | 8.83% (56/634)   |      |
|            |         | After 2010 | 9.39% (62/660)   |      |
|            | 3       | Before 2005| 6.28% (12/191)   | <0.05|
|            |         | 2005–2010  | 3.55% (45/1268)  |      |
|            |         | After 2010 | 8.08% (91/1126)  |      |
| Southwest  | 1b      | Before 2005| 36.99% (54/146)  | <0.05|
|            |         | 2005–2010  | 18.98% (41/216)  |      |
|            |         | After 2010 | 35.23% (167/474) |      |
|            | 2a      | Before 2005| 21.92% (32/146)  | <0.05|
|            |         | 2005–2010  | 6.48% (14/216)   |      |
|            |         | After 2010 | 3.04% (11/362)   |      |
|            | 3       | Before 2005| 11.21% (25/223)  | <0.05|
|            |         | 2005–2010  | 31.71% (137/432) |      |
|            |         | After 2010 | 18.88% (179/948) |      |

$P < 0.05$ indicates significant difference

### Table 4 Comparison of RNA levels of HCV with different subtypes

| Subtypes | HCV RNA levels (lg copies/ml) |
|----------|------------------------------|
|          | <10^6 | ≥10^6 |
| 1b       | 937   | 208  |
| 2a       | 62    | 41   |
| 3a       | 27    | 66   |
| 3b       | 177   |      |

(1) 1b and 2a, 3a, 3b: $P < 0.05$ (2) 2a and 3a: $P > 0.05$; 2a and 3b, 6a $P < 0.05$ (3) 3a and 3b, 6a: $P < 0.05$ (4) 3b and 6a: $P < 0.05$

### Table 5 Comparison of severity of Hepatitis with different genotypes

| Subtypes | Degree of liver disease |
|----------|-------------------------|
|          | chronic hepatitis | liver cirrhosis | hepatocarcinoma |
| 1a\*     | 8 | 1 | 1 |
| 1b        | 395 | 165 | 46 |
| 2a        | 228 | 41 | 13 |
| 3a        | 23 | 5 |  |
| 3b        | 35 | 2 |  |

\*Fisher’s exact test

(1) 1a and 1b, 2a, 3a, 3b: $P > 0.05$ (2) 1b and 2a, 3b: $P < 0.05$; 1b and 3a: $P > 0.05$ (3) 2a and 3a, 3b: $P > 0.05$ (4) 3a and 3b: $P > 0.05$
Conclusion
To sum up, HCV GTs and subtypes showed significant geographical distribution divergence in China. Along with the increasing mobility of the population, the HCV genotype distribution changes gradually. HCV GT distribution and co-infection data from our comprehensive statistical analysis in Chinese patient population provide important diagnostic and prognostic information for more effective treatment of HCV infections. In addition, more attention should be paid to intravenous drug abusing, which may have become a new risk factor for HCV transmission in China. Above all, it is urgently need to launch large-scale multi-center studies to discover the associations between HCV genotypes/subtypes and some clinical and viral factors described above. All those information are important to implement personalized and precision medicine in China for HCV infections and the relative hepatitis.

Abbreviations
HCV: Hepatitis C virus; ETVR: End of treatment virological response; GTs: Genotypes; HCC: Hepato-cellular carcinoma; HDs: Hemodialysis patients; IDUs: Intravenous drug users; LC: Liver cirrhosis; LD: Sever liver disease; LiPA: Line probe hybridization method; PCR-RDB: Polymerase chain reaction-reverse dot blot; PR: PEGylated interferon alpha and ribavirin; PTHC: Post-transfusion hepatitis; RFLP: Restriction fragment length polymorphism; SOC: Standard-of-care

Acknowledgements
Not applicable.

Funding
This study was supported by Natural Science Foundation of China (81572089).

Availability of data and materials
Please contact author for data requests.

Authors’ contributions
YZ carried out the study concept, data collection, analysis and drafting the manuscript. MH has full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. LM C gave an improved suggestion about the whole article. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Author details
1Institute of Blood Transfusion, Peking Union Medical College, Chinese Academy of Medical Sciences, Chengdu 610052, China. 2Sichuan Blood Safety and Blood Substitute, International Science and Technology Cooperation Base, Chengdu 610052, China. 3Toronto General Research Institute, University of Toronto, Toronto, ON, Canada.

Received: 5 September 2016 Accepted: 15 February 2017
Published online: 23 February 2017

References
1. Cai LN, Zhu SW, Zhou C, Wang YB, Jiang NZ, Chen H, Tang XY, Wang JH, Chen X, Hu WJ, et al. Infection status of HBV, HCV and HIV in voluntary blood donors of Chinese Nanjing area during 2010–2013. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22:1089–93.
2. CP, G A, J P, L F, Y H: Estimated Global Prevalence of Hepatitis C Virus Infection. [J] Annual Meeting 2004.
3. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19:950–8.
4. Bennett H, Waiser N, Johnston K, Kao JH, Lim YS, Duan ZP, Lee YJ, Wei L, Chen CI, Sievert W, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int. 2015;9:378–90.
5. Gower E, Estes C, Blach S, Razavi-Shaerz K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61:545–57.
6. Ye Y, Yan YS, Chen G, Yan PP, Zheng WX, Deng YQ, Yang XH, Wu SL, Zhang ZS. Molecular epidemiology of hepatitis C virus among different groups of people in the province of Fujian, China. Arch Virol. 2013;158:611–8.
7. Peng L, Lu Y, Liu W, Zhu Y, Yan X, Xu J, Wang X, Wang Y, Liu W, Sun Z. Genotype distribution and molecular epidemiology of hepatitis C virus in hubei, Central China. PloS One. 2015;10:e0137059.
8. Zhang Lx, An Y, Zhang Xq, Liu Lw, Jinzhong Y: Genotypre distribution of chronic HCV infections in Shandong. Pathogen Biol 2011;567–570.
9. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5:453–63.
10. Reed KE, Rice OM. Overview of hepatitis C virus genome structure, polypeptide processing, and protein properties. Curr Top Microbiol Immunol. 2000;242:255–84.
11. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993;74(Pt 11):2391–9.
12. Gu L, Tong W, Yuan M, Lu T, U C, Lu L. An increased diversity of HCV isolates were characterized among 393 patients with liver disease in China representing six genotypes, 12 subtypes, and two novel genotype 6 variants. J Clin Virol. 2013;57:311–7.
13. Gué G, Shaoqin G. Research on HCV genotype among hemodialysis patients in Guangzhou. J Trop Med. 2014;589:594 + 59.
14. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Hallon P, Inchauspe G, Kuiken C, Maertens G, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42:962–73.
15. An Y, Wu T, Wang M, Lu L, C, Zhou Y, Fu Y, Chen G. Conservation in China of a novel group of HCV variants dating to six centuries ago. Virology. 2014; 464:465–21.
16. Gu B, Huang H. HCV genotypes of Zhezhou and the correlation analysis of viral load. Chin J Clin Hepatitis. 2013;29:832–834.
17. Zhou Y, Yin F. Research on association between HCV viral load, genotype and antiviral effect. Practical Journal of liver disease. 2011;14;340–343.
18. Zhou Q, Li Y. HCV genotyping in Wuhan, and analysis of liver function in chronic patients and blood index. Int J Lab. Med. 2013;3:1693–1695.
19. Lu E, Tong Y. Analysis of HCV genotype in 273 HCV infectors. Xiangyang vocational and technical college. 2015;14:27–29.
20. Song S, Gui W. HCV genotype analysis of 169 cases in Wuhan. Practical journal of clinical medicine. 2015;19:36–38.
21. Huang Q, Qiao J. HCV genotype detection with PCR-RDB in Wuhan. Chinese Journal of Nosocomiology. 2011;21:2674–2676.
22. Wang J, Yuan W. Oligonucleotide array chip detection of hepatitis c virus (HCV) genotype and clinical application. Chinese Journal of Laboratory Medicine. 2005;28:1258–1252.
23. Bao A, Li Y, Tong Y, Zhe H, Wu W. HCV genotyping of chronic patients and therapeutic effect evaluation in Hubie. J Mod Lab. 2013;28:13–6.
24. Wu Z, Li Y. HCV genotyping results of 254 cases in Wuhan. Journal of Modern Laboratory Medicine. 2014;2012:146–126.
25. Li W, Zeng Y. HCV genotype distribution research among chronic HCV infectors in Henan. The diagnosis and treatment of practical magazine. 2015;25:538–539.
26. Cheng S, Zhang B, Zhao L, Guo R, Xu Y, Li W, Fang J. HCV genotyping for HCV carrier donors and HCV patients. Chinese Journal of Misdiagnostics. 2003;3:1330–1331.
90. Zhou Z, Xu H. HCV genotype distribution and its clinical significance in Chongqing. Journal of Chongqing Medical University. 2015;40:383–387.

91. Liang Y, Yang X. HCV genotype in HCV patients in Guiyang and correlation studies associated with the peripheral helper T cell factor expression. Guizhou Medical Journal. 2015;39:301–305.

92. Liang Y. HCV genotype in HCV patients and the correlation analysis associated with serum viral load and Blood biochemical cytokine index. Guizhou Medical Journal. 2015;39:14–17.

93. Li Y, Bi S. Correlation analysis of hepatitis c virus genotype, viral load and peripheral blood T lymphocyte subgroup in HCV patients of Kunming. The Chinese journal of liver disease. 2015;23:142–144.

94. Yang X, Yue D, Li Y. HCV genotyping status in Guizhou. Journal of Guizhou Medical College. 2014;39:486–489.

95. Li Z, Gao Y. HCV genotyping research based on NSS5 region. International Journal of Laboratory Medicine. 2013;25:50–55.

96. Lei H, Dai J. HCV genotype and its clinical significance among HCV patients in Kunming. Hepatology. 2011;16:48–49.

97. Song H, Yi X. The HCV infection status in Tibet Tibetan crowd and HCV genotype analysis. Gastroenterology and Liver disease. 1997;6:315–317.

98. Gonza Yu Zheng GJ. The preliminary study of hepatitis c virus (HCV) genotypes among Tibetan population. Tibetan medicine journal. 1996;9:10–65.

99. Zhang Z, Xu H. HCV genotype distribution and its clinical significance in HCV patients in Guizhou and correlation studies associated with the peripheral helper T cell factor expression. Guizhou Medical Journal. 2015;39:301–305.

100. Liu B, Wang Y. HCV genotyping research on 69 cases in Chongqing. Journal of Chongqing Medical University. 2015;40:383–387.

101. Su X, Niu J. HCV genotyping investigation in Jinlin. Chinese journal of public health. 1997;16:548.

102. He P, Chen C. HCV genotyping research. Journal of Medical Focus. 2010;31:10–11.

103. Yan X, Wu W, Wei L. HCV genotyping research on 90 cases. Acta Academicae Medicinae Xuzhou. 1997;7:14–15.

104. Zhang Z, Zhang Y, Wang J, Yang W. HCV genotyping in chronic HCV infectors and research on relationship with HCV RNA level. Journal of Clinical Hepatology. 2012;15:321–323.

105. Li M, Tao G. HCV genotype characteristics in Baiyin. The Western Medicine. 2011;33:2960.

106. Li Z, Jiang Y, Li H. Hepatitis c genotype distribution research on 82 HCV patients of Jiangxi. Acta Acad Med Jiangxi. 2000;39:831.

107. Chen Z, Liu J, Meng C, Zhang Z, Zhang C. HCV genotyping study in the China. Chin J Clin Hepatol. 2010;290–291 + 294.

108. Chen Q, Guo Z, Xiao P, Yang Y, Xiong Y, Yue W. HCV serotyping and genotyping and study on the relationship with the interferon antibody in Gansu. International Journal of Laboratory. 2006;27:612–614.

109. Peng C, Mao X. HCV genotyping analysis of the Han chinese people in Gansu. Chin J Clin Hepatol. 2013;29:828–831.

110. Xu H, Yang W. Research on HCV genotyping Dongxiang Autonomous County of Gansu. Molecular diagnosis and therapy. 2012;41:111–114.

111. Xu H, Ju J. HCV genotyping research in a region. International Journal of Laboratory Medicine. 2012;33:683–684.

112. Wang J. Different genotype distribution characteristics in southern Gansu. Laboratory Medicine and Clinic. 2014;11:2364–2365.

113. Li M, Tao G. HCV genotype characteristics in Baiyin. The Western Medicine. 2014;27:63–65.

114. Yang W, Xu H. Genotypes characteristics HCV infection in four different ethnicity of Gansu. Journal of gansu college of traditional Chinese medicine. 2013;30:27–30.

115. Yang J, Li Z, Tian S. Relationship between the autoantibodies dynamic change and the HCV - RNA genes. International Journal of Laboratory Medicine. 2012;33:2960–2962.

116. Xu H, Yang W. Research on HCV genotyping Dongxiang Autonomous County of Gansu. Molecular diagnosis and therapy. 2012;41:111–114.

117. Xu H, Ju J. HCV genotyping research in a region. International Journal of Laboratory Medicine. 2012;33:683–684.

118. Liang C. HCV genotyping among chronic HCV inflicants and antiviral therapeutic effect analysis in Weiwu. Gansu Medical Journal. 2012;31:900–902.

119. Zhang W, Liu L, Du S. HCV genotype distribution characteristics in Lanzhou, China. Chin J Clin Hepatol. 2010;290–291 + 294.

120. Chen Q, Guo Z, Xiao P, Yang Y, Xiong Y, Yue W. HCV serotyping and genotyping and study on the relationship with the interferon antibody in Gansu. International Journal of Laboratory. 2006;27:612–614.

121. Peng C, Mao X. HCV genotyping analysis of the Han chinese people in Gansu. Chin J Clin Hepatol. 2013;29:828–831.

122. Xu H, Yang W. Research on HCV genotyping in Tibetan of Gansu. International Journal of Laboratory Medicine. 2012;2081:2082 + 2084.

123. Li Q, Han F, Wang X. Hapatic c genotype situation analysis in Wuwei area. The Chinese community physicians. 2011;13:319.

124. Liu T, Chen Z. HCV genotyping research on Uighur and han Chinese people in Xinjiang. Chinese Journal of Nosocomiology. 2015;25:422–4124.

125. Chen Z, Liu J, Meng C, Zhang Z, Zhang C. HCV genotyping study among han, uygur, kazak patients in Xinjiang. J Xinjiang Med Univ. 2015;855:857 + 861.

126. Xu X, Qin J. HCV genotype distribution among uighurs in Xinjiang. The Experimental and Clinical Virology Journal. 2014;38:26–267.

127. Huang Y, Han F. Epidemiological characteristics and analysis of 110 HCV infectors. Chin J Clin Hepatol. 2014;30:505–507.

128. Abdulhalilhi H, Shi G. HCV genotyping analysis od 118 cases in Xinjiang. The Chinese journal of liver disease. 2011;19:127–128.
211. Wang Y, Xia X, Li C, Maneekam N, Xia W, Zhao W, Feng Y, Kung HF, Fu Y, Lu L. A new HCV genotype 6 subtype designated 6w was confirmed with three complete genome sequences. J Clin Virol. 2009;46:195–9.

212. Xia X, Lu L, Tee KK, Zhao W, Wu J, Yu J, Li X, Lin Y, Mukhtar MM, Hagedorn CH, Takebe Y. The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China. J Med Virol. 2008;80:1142–52.

213. Xia X, Zhao W, Tee KK, Feng Y, Takebe Y, Li Q, Pybus OG, Lu L. Complete genome sequencing and phylogenetic analysis of HCV isolates from China reveals a new subtype, designated 6u. J Med Virol. 2008;80:1740–6.

214. Xu R, Tong W, Gu L, Li C, Fu Y, Lu L. A panel of 16 full-length HCV genomes was characterized in China belonging to genotypes 1–6 including subtype 2f and two novel genotype 6 variants. Infect Genet Evol. 2013;20:225–9.

215. Su Y, Liu H. Hepatitis C virus genotype distribution in China. Chin J Epidemiol. 2013;34:80–4.

216. Zhang C, Wu N, Liu J, Ge Q, Huang Y, Ren Q, Feng Q, He G. HCV subtype characterization among injection drug users: implication for a crucial role of Zhejiang in HCV transmission in China. PLoS One. 2011;6:e18817.

217. Dong ZX, Zhou HL, Wang JH, Xiang XG, Zhuang Y, Guo SM, Gui HL, Zhao GD, Tang WL, Wang H, Xie Q. Distribution of hepatitis C virus genotypes in Chinese patients with chronic hepatitis C. correlation with patients’ characteristics and clinical parameters. J Dig Dis. 2012;13:564–70.

218. Nie H, Chen J. Hepatitis C virus genotype distribution of research on Chinese Han population with chronic HCV infection. Chin J Epidemiol. 2012;33:501–4.

219. Ge X, Wang S, Li D, Mizokami M, Wu R, Huang G, Li Y, Wang Y, Wang Y, Cao K, et al.: Molecular biology research on HCV seroblogica genotype and subtypes in IDUs, patients and blood donors in Guangxi. The experimental and clinical virology journal 1996;3:312–17.

220. Chen YD, Liu MY, Yu WL, Li JQ, Peng M, Da Q, Liu X, Zhou QZ. HCV. C. virus infections and genotypes in China. Hepatobiliary Pancreat Dis Int. 2002;1:194–201.

221. Wang y, Chen c. Hepatitis c genotyping and clinical significance In The fifth international conference on clinical virology (pp. 312–317). 1996.

222. Xia X, Lu L, Tee KK, Zhao W, Wu J, Yu J, Li X, Lin Y, Mukhtar MM, Hagedorn CH, Takebe Y. Hepatitis C genotyping and clinical significance. J Dig Dis. 2012;13:564–70.

223. Wang Y, Xia X, Li C, Maneekarn N, Xia W, Zhao W, Feng Y, Kung HF, Fu Y, Lu L. A new HCV genotype 6 subtype designated 6w was confirmed with three complete genome sequences. J Clin Virol. 2009;46:195–9.

224. Xia X, Zhao W, Tee KK, Feng Y, Takebe Y, Li Q, Pybus OG, Lu L. Complete genome sequencing and phylogenetic analysis of HCV isolates from China reveals a new subtype, designated 6u. J Med Virol. 2008;80:1142–52.

225. Xia X, Zhao W, Tee KK, Feng Y, Takebe Y, Li Q, Pybus OG, Lu L. Complete genome sequencing and phylogenetic analysis of HCV isolates from China reveals a new subtype, designated 6u. J Med Virol. 2008;80:1740–6.

226. Xu R, Wang M, Qiu Y. C: Hepatitis c virus (HCV) infection with different transmission routes. China Public Health. 2013;29:809–10.
261. Omata M, Kanda T, Yu M, Yokosuka O, Lim SG, Jafri W, Tateishi R, Hamid SS, Chuang WL, Chutaputti A, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012;6:409–35.

262. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.

263. Saito T, Ito T, Ishiko H, Yonaha M, Morikawa K, Miyokawa A, Mitamura K. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b. Am J Gastroenterol. 2003;98:1377–83.

264. Hazari S, Taylor L, Haque S, Garry RF, Florman S, Luftig R, Regenstein F, Dash S. Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. Virol J. 2007;4:89.

265. Afzal S, Idrees M, Akram M, Awan Z, Khubaib B, Aftab M, Fatima Z, Badar S, Hussain A. Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients. Virol J. 2012;7:277.

266. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science. 1999;285:107–10.

267. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;348:g3308.

268. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146:1176–92.

269. Lee R, Kottilil S, Wilson E. Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. Hepatology International, 2016;10:1-506.

270. Antón J M M. Abstracts of the 25th Annual Conference of APASL, February 20-24, 2016, Tokyo, Japan. Hepatology International, 2016;10:1-506.

271. Gan XM, Li W. Opportunities and challenges of HCV treatment. Journal of kunming medical university. 2014;35:1–3.